BACKGROUND: Previous groups have shown contralateral submandibular gland sparing to improve xerostomia with safe outcomes, but primarily in early-stage disease. In this study, we present a large cohort of @entity1 with locally advanced @entity135 that underwent contralateral submandibular gland-sparing radiotherapy, to demonstrate feasibility and safety specifically in @entity1 with locally advanced disease. METHODS: We retrospectively analyzed @entity1 who were treated prospectively with contralateral submandibular gland sparing. Only @entity1 who underwent bilateral neck radiotherapy with contralateral submandibular gland doses <39 Gy were included. RESULTS: We identified 71 @entity1 . Approximately 80% of @entity1 had >= N2b disease. The contralateral submandibular gland mean dose was 33 Gy and, at a median follow-up of 27.3 months, no @entity1 experienced treatment failure in the contralateral level IB lymph nodes. CONCLUSION: Xerostomia remains a significant morbidity despite parotid sparing and can be minimized further by contralateral submandibular gland sparing. These data provide important preliminary evidence that contralateral submandibular gland sparing is feasible and may be safe even in locally advanced @entity5 .    2014 Wiley Periodicals, Inc. Head Neck, 2015.

Safety of contralateral submandibular gland sparing in locally advanced XXXX : A multicenter review.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers']
@entity5 :: (MESH:D009369,Disease) :: ['oropharyngeal cancers']
